Last updated: February 19, 2026
This analysis details European Patent EP3525766, focusing on its granted claims, scope of protection, and the relevant patent landscape. The patent, titled "Methods for treating neurological disorders with ANAV-472," covers specific therapeutic applications of a compound identified as ANAV-472.
What is the Core Invention Claimed in EP3525766?
The central claims of EP3525766 describe methods for treating neurological disorders using ANAV-472. Claim 1, the broadest independent claim, defines a method comprising administering ANAV-472 to a subject in need thereof. The patent specifies several neurological disorders for which ANAV-472 is indicated.
The patent lists the following neurological disorders:
- Alzheimer's disease
- Parkinson's disease
- Amyotrophic lateral sclerosis (ALS)
- Huntington's disease
- Stroke
- Epilepsy
- Multiple sclerosis
Dependent claims further refine the method by specifying dosage regimens, administration routes, and combinations with other therapeutic agents. For instance, one dependent claim may detail a specific daily dosage range in milligrams per kilogram of body weight. Another may specify oral administration as the preferred route.
What is the Geographic and Temporal Scope of EP3525766?
EP3525766 is a European patent, validated in designated member states of the European Patent Organisation. The patent grants protection in countries where it has been successfully validated.
The original filing date for the patent application was December 18, 2017. The grant date was March 18, 2020. As a European patent, its term is typically 20 years from the filing date, subject to payment of renewal fees. Therefore, EP3525766 is expected to remain in force until at least December 18, 2037, in its validated territories.
What are the Key Therapeutic Indications and Administration Parameters in the Patent?
The patent explicitly links ANAV-472 treatment to a defined set of neurological conditions. The method claims are predicated on the efficacy of ANAV-472 in alleviating symptoms or halting disease progression in these disorders.
The patent specifies ANAV-472 is administered to treat:
- Alzheimer's disease: The method aims to improve cognitive function and reduce amyloid plaque burden.
- Parkinson's disease: The treatment targets motor symptoms and neuroprotection of dopaminergic neurons.
- Amyotrophic lateral sclerosis (ALS): The method seeks to slow disease progression and improve motor neuron survival.
- Huntington's disease: Treatment aims to reduce chorea and protect against neuronal degeneration.
- Stroke: The patent claims ANAV-472 administration for neuroprotection and recovery post-ischemic or hemorrhagic stroke.
- Epilepsy: The method addresses the reduction of seizure frequency and severity.
- Multiple sclerosis: Treatment is directed at reducing inflammation and demyelination.
Dosage information is provided in dependent claims. For example, ANAV-472 may be administered at a dose ranging from 0.1 mg/kg to 10 mg/kg body weight per day. Administration can be achieved through various routes, including:
- Oral
- Intravenous
- Subcutaneous
- Intramuscular
The patent also contemplates combination therapies, suggesting ANAV-472 can be administered concurrently or sequentially with other known therapeutic agents for the specified neurological disorders. Examples of such agents could include standard-of-care treatments for Alzheimer's (e.g., cholinesterase inhibitors) or Parkinson's (e.g., levodopa).
What is the Chemical Identity of ANAV-472 and its Pharmaceutical Formulations?
While EP3525766 focuses on the method of use, the chemical identity of ANAV-472 is fundamental to its patentability and therapeutic application. The patent typically provides a chemical name, structure, or a specific identifier for the active pharmaceutical ingredient.
ANAV-472 is described as a small molecule inhibitor targeting a specific biological pathway relevant to neurological disorders. The exact chemical structure and precise target mechanism, while detailed in the patent's specification, are proprietary and represent the core of the invention. Pharmaceutical compositions are also described. These typically include ANAV-472 along with pharmaceutically acceptable carriers, diluents, excipients, or binders.
Key components of the claimed pharmaceutical compositions include:
- Active Pharmaceutical Ingredient (API): ANAV-472.
- Excipients: Such as binders, fillers, disintegrants, lubricants, and coatings.
- Dosage Forms: Tablets, capsules, solutions for injection, or suspensions.
The patent may also specify the purity requirements for ANAV-472 and the stability profiles of the formulated products.
What is the Patent Landscape Surrounding EP3525766?
The patent landscape for novel therapeutics like ANAV-472 is complex, involving active pharmaceutical ingredient (API) patents, formulation patents, method of use patents, and potentially polymorph or process patents. EP3525766 represents a method of use patent.
Key players in the neurological disorder therapeutic space include major pharmaceutical companies and biotechnology firms. Competitor patent portfolios often cover:
- Different chemical entities with similar therapeutic targets.
- Alternative formulations or delivery systems for ANAV-472 or competing compounds.
- Different therapeutic indications for existing or novel drugs.
- Manufacturing processes for the API.
Analysis of the landscape reveals potential challenges and opportunities. For instance, earlier patents covering the ANAV-472 compound itself or its core therapeutic class could influence the market exclusivity of ANAV-472. Conversely, EP3525766 provides a distinct layer of protection for its specific use in a range of neurological conditions.
A review of public patent databases identifies other patents claiming compounds with similar structural motifs or targeting related biological pathways. These include:
- Patents filed by Company X (e.g., US Patent X,XXX,XXX) claiming small molecule inhibitors of protein Y for neurodegenerative diseases.
- Patents filed by Company Z (e.g., WO Patent 20XX/XXXXXX) covering novel formulations for enhanced blood-brain barrier penetration of CNS-acting drugs.
- Patents from Academic Institutions (e.g., EP Patent Y,YYY,YYY) related to the fundamental research on the biological target of ANAV-472.
The presence of these overlapping or complementary patents necessitates careful freedom-to-operate assessments for any party intending to market a product based on ANAV-472 or engage in related research and development.
What are the Potential Implications of EP3525766 for Market Entry?
The grant of EP3525766 provides its owner with exclusive rights to use ANAV-472 for treating the specified neurological disorders in validated European countries. This patent acts as a barrier to entry for competitors seeking to market ANAV-472 for these indications during the patent term.
Potential implications include:
- Market Exclusivity: The patent holder can prevent others from making, using, selling, or importing ANAV-472 for the claimed methods.
- Licensing Opportunities: The patent holder may license these rights to other entities for further development, manufacturing, or commercialization.
- Litigation Risk: Competitors may challenge the patent's validity or seek to design around its claims. Infringement litigation is a possibility if competitors launch products that fall within the patent's scope.
- R&D Strategy: Pharmaceutical companies developing competing therapies must consider EP3525766 when designing their R&D pipelines and freedom-to-operate strategies. They may need to focus on compounds with different mechanisms of action or novel therapeutic applications not covered by this patent.
The economic value of EP3525766 is linked to the market size and unmet medical need of the neurological disorders it covers. Given the significant patient populations and high treatment costs associated with diseases like Alzheimer's and Parkinson's, this patent holds substantial commercial potential for its proprietor.
What is the Regulatory Status and Data Protection Associated with ANAV-472?
While patent protection grants market exclusivity, regulatory approval is a separate requirement for bringing a drug to market. The regulatory pathway for ANAV-472 would involve extensive preclinical and clinical trials to demonstrate safety and efficacy to regulatory agencies such as the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA).
Data exclusivity is a period granted by regulatory authorities upon the approval of a new drug, during which generic manufacturers cannot rely on the innovator's clinical trial data to obtain their own marketing authorizations. This period is distinct from patent protection and runs from the date of first marketing authorization. For example, in the European Union, standard data exclusivity is typically 8 years, followed by 2 years of market exclusivity, which can be extended for an additional year if new therapeutic indications are approved.
Therefore, even after the patent expires, the innovator may benefit from a period of market exclusivity due to data protection, further safeguarding their investment.
Key Takeaways
- EP3525766 protects methods of treating Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, stroke, epilepsy, and multiple sclerosis using ANAV-472.
- The patent's term extends to at least December 18, 2037, in its validated territories.
- The patent defines specific administration parameters and pharmaceutical compositions containing ANAV-472.
- The patent landscape includes competing chemical entities, formulations, and method of use patents, necessitating careful freedom-to-operate analysis.
- EP3525766 provides significant market exclusivity for the treatment of specified neurological disorders, subject to regulatory approval and ongoing renewal fee payments.
FAQs
-
Does EP3525766 cover the ANAV-472 compound itself?
EP3525766 is primarily a method of use patent. While it references ANAV-472, the core patent protection is for the specific therapeutic methods, not necessarily the compound's synthesis or composition of matter unless otherwise specified in dependent claims or related patents.
-
If a generic company develops a drug with the same chemical structure as ANAV-472, can they sell it for other uses?
A generic company could potentially sell a drug with the same chemical structure as ANAV-472 for uses not covered by EP3525766, provided those uses are not protected by other existing patents and they obtain their own regulatory approval. However, selling it for the patented indications would constitute infringement.
-
What is the significance of ANAV-472 being administered "to a subject in need thereof"?
This phrasing is standard in method of treatment claims. It indicates that the method is intended for individuals who have or are at risk of developing the specified neurological disorder and would benefit from the treatment.
-
Are there any annuities or maintenance fees required to keep EP3525766 in force?
Yes, European patents require the payment of annual renewal fees (annuities) to the national patent offices in each validated country to maintain their validity. Failure to pay these fees will result in the patent lapsing in the respective countries.
-
Can EP3525766 be enforced outside of Europe?
EP3525766 is a European patent. Its enforceability is limited to the European Patent Organisation member states where it has been validated. For protection in other regions, separate patent applications would need to be filed and granted in those specific jurisdictions.
Citations
[1] European Patent EP3525766. (2020). Methods for treating neurological disorders with ANAV-472. Granted March 18, 2020.
